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Abstract
Background:  The current epidemics of type 2 diabetes mellitus (T2DM), non-alcoholic
steatohepatitis (NASH), and Alzheimer's disease (AD) all represent insulin-resistance diseases.
Previous studies linked insulin resistance diseases to high fat diets or exposure to streptozotocin,
a nitrosamine-related compound that causes T2DM, NASH, and AD-type neurodegeneration. We
hypothesize that low-level exposure to nitrosamines that are widely present in processed foods,
amplifies the deleterious effects of high fat intake in promoting T2DM, NASH, and
neurodegeneration.
Methods: Long Evans rat pups were treated with N-nitrosodiethylamine (NDEA) by i.p. Injection,
and upon weaning, they were fed with high fat (60%; HFD) or low fat (5%; LFD) chow for 6 weeks.
Rats were evaluated for cognitive impairment, insulin resistance, and neurodegeneration using
behavioral, biochemical, molecular, and histological methods.
Results:  NDEA and HFD ± NDEA caused T2DM, NASH, deficits in spatial learning, and
neurodegeneration with hepatic and brain insulin and/or IGF resistance, and reductions in tau and
choline acetyltransferase levels in the temporal lobe. In addition, pro-ceramide genes, which
promote insulin resistance, were increased in livers and brains of rats exposed to NDEA, HFD, or
both. In nearly all assays, the adverse effects of HFD+NDEA were worse than either treatment
alone.
Conclusions: Environmental and food contaminant exposures to low, sub-mutagenic levels of
nitrosamines, together with chronic HFD feeding, function synergistically to promote major insulin
resistance diseases including T2DM, NASH, and AD-type neurodegeneration. Steps to minimize
human exposure to nitrosamines and consumption of high-fat content foods are needed to quell
these costly and devastating epidemics.
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Background
Alzheimer's Disease (AD), obesity, type 2 diabetes melli-
tus (T2DM), and non-alcoholic fatty liver disease
(NAFLD)/non-alcoholic steatohepatitis (NASH), which
includes metabolic syndrome, have sharply increased in
prevalence over the past several decades [1-6]. In addition,
we have noted striking increases in age-specific AD mor-
tality rates over the same time interval, and correlated
these findings with sharply increased consumption of
processed foods, use of preservatives, and demand for
nitrogen-containing fertilizers [7]. Such rapid shifts in
age-adjusted AD morbidity and mortality are more con-
sistent with exposure-related rather than genetic etiolo-
gies. A common theme resonating from these lifestyle
trends is that we have increased our exposures to nitro-
samines (R1N(-R2)-N = O) and related compounds.
Nitrosamines form by chemical reactions between nitrites
and secondary amines or proteins, and they exert toxic or
mutagenic effects by promoting DNA damage, oxidative
stress and reactive oxygen species generation [8]. The end
result is increased lipid peroxidation, adduct formation,
and pro-inflammatory cytokine activation [9], which also
happen to be major mediators of human insulin-resist-
ance diseases, including T2DM, NASH, and AD [10-16].
The notion that chronic injury caused by alkylating agents
could lead to malignant transformation and/or tissue
degeneration is consistent with the findings that: 1)
chronic exposure to tobacco nitrosamines causes both
lung cancer and emphysema with chronic obstructive pul-
monary disease; and 2) treatment with streptozotocin
(STZ), a nitrosamine-related compound, causes hepato-
cellular carcinoma, pancreatic carcinoma, malignant
brain tumors, T2DM, neurodegeneration, and/or hepatic
steatosis, depending on dose and route of administration
[17-25]. Therefore, better characterization of the non-neo-
plastic and degenerative effects of nitrosamines is war-
ranted.
STZ, like other N-nitroso compounds, functions as: 1) an
alkylating agent and potent mutagen [17]; 2) an inducer
of DNA adducts leading to apoptosis [26]; 3) a mediator
of unscheduled DNA synthesis, triggering cell death [17];
4) an inducer of single-strand DNA breaks and stimulus
for nitric oxide (NO) formation following breakdown of
its nitrosamine group [19]; and 5) an enhancer of the xan-
thine oxidase system leading to increased production of
superoxide anion, H2O2, and OH-  radicals [27]. Ulti-
mately, STZ-induced injury and DNA damage promote
mitochondrial dysfunction [19], ATP deficits [28], and
cell death. The structural similarities between STZ and nit-
rosamines, including N-nitrosodiethylamine (NDEA) and
N-nitrosodimethylamine (NDMA) [29], together with
experimental evidence that high doses of STZ cause cancer
while lower doses cause diabetes or AD-type neurodegen-
eration with cognitive impairment [18,19,25], led us to
hypothesize that while high doses of nitrosamine expo-
sures cause cancer, lower, sub-mutagenic doses may pro-
mote insulin resistance-mediated degenerative diseases.
There is growing evidence that obesity, T2DM, and cogni-
tive impairment are inter-related based on findings that:
1) the risk of developing mild cognitive impairment
(MCI), dementia, or AD is increased in individuals with
T2DM [10,30] or obesity/dyslipidemic disorders [31]; 2)
brain insulin resistance and insulin deficiency progress
with severity of AD [32-35]; 3) experimental models of
T2DM and/or obesity exhibit MCI [36,37] and neurode-
generation with brain insulin resistance [38,39]; 4) exper-
imentally induced brain insulin resistance and insulin
deficiency cause AD-type neurodegeneration and cogni-
tive impairment [24,25,40-42]; 5) insulin sensitizer
agents or intranasal insulin [43-49] can improve cognitive
performance in experimental models of AD [22] or in
humans with AD or MCI; and 6) similar molecular, bio-
chemical, and mechanistic abnormalities in T2DM,
NASH, and AD [10-14,16,50]. However, chronic high fat
diet (HFD)-induced obesity that leads to NASH and
T2DM is not sufficient to cause AD; instead, the associated
neurodegeneration is relatively mild, despite brain insulin
resistance [38,39]. Correspondingly, most individuals
with T2DM do not develop AD, and the vast majority of
individuals with AD are neither obese nor diabetic. There-
fore, some additional co-factors must determine who
among the at-risk population will likely develop AD.
Herein, we examined the hypothesis that early sub-muta-
genic exposure to NDEA and chronic HFD feeding addi-
tively or synergistically mediate the triad of major insulin
resistances diseases, including T2DM, NASH, and AD-type
neurodegeneration with cognitive impairment.
Materials and methods
Materials
Chow high fat (D12492-60% of calories) and low fat
(D12450B-10% of calories) diets were commercially pre-
pared by Research Diets, Inc. (New Brunswick, NJ). Rab-
bit, mouse, or goat generated monoclonal or polyclonal
antibodies to ubiquitin, tau, phospho-tau (AT8-S199,
S202, T205), glial fibrillary acidic protein (GFAP), 4-
hydroxy-2-nonenal (HNE), choline acetyltransferase
(ChAT), amyloid precursor protein amyloid-β peptide
(Aβ PP-Aβ),  β-actin, were purchased from Chemicon
(Tecumsula, CA), CalBiochem (Carlsbad, CA), or Molec-
ular Probes (Eugene, OR). All other polyclonal and mon-
oclonal antibodies and immunodetection reagents were
purchased from Abcam (Cambridge, MA), Vector Labora-
tories (Burlingame, CA), Upstate (Billerica, MA), Chemi-
con (Temecula, CA), or Molecular Probes (Eugene, OR).
The insulin ultra-sensitive ELISA kit was obtained from
ALPCO Diagnostics (Salem, NH). Histochoice fixativeMolecular Neurodegeneration 2009, 4:54 http://www.molecularneurodegeneration.com/content/4/1/54
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was purchased from Amresco, Inc (Solon, OH). Infinity
Alanine aminotransaminase (ALT/GPT) assay kits were
purchased from Fisher Diagnostics (Middletown, VA).
Antibodies to tumor necrosis factor-α (TNF-α) and inter-
leukin-1β (IL-1β) were purchased from Invitrogen
(Carlsbad, CA). Antibodies to Akt, phospho-Akt
(Thr308), GSK3β, and phospho-GSK-3β (Ser9) were pur-
chased from Cell Signaling (Danvers, MA). The Amplex
Red Cholesterol Assay Kit and Amplex UltraRed soluble
fluorophore were purchased from Invitrogen (Carlsbad,
CA). MaxiSorb 96-well plates used for ELISAs were from
Nunc (Thermo Fisher Scientific; Rochester, NY). The Top-
Count NXT and ATP Lite assay kit were from Perkin-Elmer
(Waltham, MA). Superblock-TBS, horseradish peroxidase
conjugated antibodies, and SuperSignal Enhanced
Chemiluminescence Reagent were from Pierce Chemical
Co (Rockford, IL). QIAzol Lysis Reagent for RNA extrac-
tion and QuantiTect SYBR Green PCR Mix were obtained
from Qiagen, Inc (Valencia, CA). The AMV 1st Strand
cDNA Synthesis kit was purchased from Roche Applied
Science (Indianapolis, IN). [125I]-Labeled recombinant
insulin and IGF-I polypeptides were purchased from GE
Healthcare (Picataway, NJ), and unlabeled recombinant
insulin and IGF-1 polypeptides were purchased from
Bachem Americas, Inc. (Torrance, CA). The Serum Triglyc-
eride Determination kit and synthetic oligonucleotides
used in quantitative polymerase chain reaction (qPCR)
assays were purchased from Sigma-Aldrich Co (St. Louis,
MO). Fine chemicals were purchased from CalBiochem
(Carlsbad, CA) or Sigma-Aldrich (St. Louis, MO).
Experimental Model
Postnatal day 3 (P3) Long Evans rat pups (mean body
weight 10 g) were given 3 alternate day intra-peritoneal
(i.p.) injections of 20 μg NDEA or vehicle. Upon weaning,
rats (N = 8-10 per group) were pair-fed for 6 weeks with
high fat (HFD) or low fat (LFD) chow diets. The HFD sup-
plied 60% of the kcal in fat (54% from lard, 6% from soy-
bean oil), 20% in carbohydrates, and 20% in protein,
whereas the LFD supplied 10% of the kcal in fat (4.4%
from lard, 5.6% from soybean oil), 70% in carbohydrates,
and 20% in protein. The use of young rats enabled us to
compare results with previous observations in the STZ
model [51]. Moreover, longitudinal studies of nuns
revealed that neuro-cognitive deficits precede the onset of
dementia by decades [52,53], suggesting that early life
exposures may contribute to the pathogenesis of AD.
Rats were weighed weekly, and food consumption was
monitored daily. At the end of the feeding period, the rats
were then subjected to Morris Water Maze testing of spa-
tial learning and memory [22,25]. Then, after an over-
night fast (14 hours), rats were sacrificed by i.p. injection
of pentobarbital (120 mg/kg), and blood, pancreas, liver,
and brain (temporal lobes) were harvested. Blood or
serum was used to measure glucose, insulin, cholesterol,
triglyceride, free fatty acid, and alanine transaminase
(ALT) as previously described [38,39]. The tissues were
used for histological, biochemical, and molecular studies.
For histological studies, tissues were immersion fixed in
Histochoice, embedded in paraffin, and sections (5-μm
thick) were stained with Hematoxylin and Eosin (H&E-
liver and pancreas) or Luxol fast blue, H&E (temporal
lobes) and examined under code. For molecular and bio-
chemical studies, liver and temporal lobe samples were
snap-frozen in a dry ice-methanol bath and stored at -
80°C [22,25,38,39]. The temporal lobes were studied
because they: 1) require intact insulin/IGF signaling
mechanisms to maintain structural and functional integ-
rity [51,54]; 2) are severely damaged by i.c.-STZ mediated
neurodegeneration [22,25]; and 3) are major targets of
neurodegeneration in AD [51]. Our experimental proto-
col was approved by the Institutional Animal Care and
Use Committee at Lifespan-Rhode Island Hospital, and
conforms to the guidelines set by the National Institutes
of Health.
Morris Water Maze Testing
Morris Water Maze testing [55] of spatial learning and
memory was performed on 4 consecutive days as previ-
ously described [22,25]. On the first day of testing, the rats
were oriented to the water maze and educated about the
location of the platform. On the 3 subsequent days of test-
ing, the platform was submerged just below the surface,
and rats were tested for learning and memory by measur-
ing the latency period required to reach and recognize the
platform. The rats were placed in the same quadrant of the
water maze for every trial on Days 1 and 2, but on days 3
and 4, the start locations were randomized. Data from all
3 trials on each day were used to calculate latency area
under the curve. Inter-group comparisons were made
using the Kruskal-Wallis one-way ANOVA and Dunn's
multiple comparison post-hoc test of significance.
Lipid Assays
Lipid analyses were performed with serum samples and
chloroform-methanol (2:1) extracted fresh frozen liver tis-
sue homogenates [38]. Total lipid content was measured
using a Nile Red fluorescence-based assay [56-58], and
fluorescence intensity (Ex 485/Em 572) was measured in
a SpectraMax M5 microplate reader (Molecular Devices
Corp., Sunnyvale, CA). Triglycerides, cholesterol, and free
fatty acids were measured with commercially available
assay kits.
Quantitative Reverse Transcriptase Polymerase Chain 
Reaction (qRT-PCR) Assays of Gene Expression
Total RNA was reverse transcribed with random primers,
and the cDNA templates were PCR amplified with geneMolecular Neurodegeneration 2009, 4:54 http://www.molecularneurodegeneration.com/content/4/1/54
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specific primer pairs [25] (Table 1). The amplified prod-
ucts were detected and analyzed in triplicate using the
Mastercycler ep realplex instrument and software (Eppen-
dorf AG, Hamburg, Germany) [38,59]. Relative mRNA
abundance was calculated from the ng ratios of mRNA to
18S rRNA measured in the same samples, and those data
were used for inter-group comparisons. Control studies
included analysis of: 1) template-free reactions; 2) RNA
that had not been reverse transcribed; 3) RNA samples
pre-treated with DNAse I; 4) samples treated with RNAse
A prior to the reverse transcriptase reaction; and 5)
genomic DNA. All assays were performed in triplicate.
Enzyme-Linked Immunosorbant Assay (ELISA)
Tissues were homogenized in radioimmunoprecipitation
assay buffer containing protease and phosphatase inhibi-
tors [39]. Direct ELISAs were performed in 96-well Max-
isorb plates [60]. In brief, proteins (40 ng/100 μl)
adsorbed to well bottoms by over night incubation at
4°C, were blocked with 1% BSA in phosphate buffered
saline (PBS), and then incubated with primary antibody
(0.2-1.0 μg/ml) for 1 hour at 37°C. Immunoreactivity was
detected with horseradish peroxidase (HRP)-conjugated
secondary antibody (1:10000) and UltraRed soluble
fluorophore [60].
For capture ELISAs used to measure pro-inflammatory
cytokines, capture antibodies (1 μg/ml) were adsorbed to
the well bottoms overnight, and after blocking for 3 hours
at room temperature with 1% BSA prepared in PBS +
0.05% Tween-20, 50 ng of liver homogenate protein were
added to each well in a 100 μl volume, and incubated for
2 hours at room temperature. Reactions were then incu-
bated with biotinylated detection antibodies (0.2 μg/ml
for IL-1β and TNFα, and 0.5 μg/ml for IL-6) for 2 hrs at
room temperature. Immunoreactivity was revealed with
HRP-conjugated Streptavidin and Amplex UltraRed. Fluo-
rescence was measured (Ex 568/Em 581) in a SpectraMax
M5 microplate reader. Binding specificity was determined
from parallel negative control incubations with the pri-
mary or secondary antibody omitted. Immunoreactivity
was normalized to protein content in parallel wells as
determined with the NanoOrange Protein Quantification
Kit.
Receptor Binding Assays
Competitive equilibrium binding studies were used to
measure effects of NDEA and HFD feeding on insulin and
IGF-I receptor binding in liver and temporal lobe [39,61].
For total binding, NP-40 lysis buffer homogenates were
incubated with 50 nCi/ml of [125I] (2000 Ci/mmol; 50
pM) insulin or IGF-I in binding buffer (100 mM HEPES
(4-(2-hydroxyethyl)-1-piperazine-ethanesulfonic acid),
pH 8.0, 118 mM NaCl, 1.2 mM MgSO4, 8.8 mM dextrose,
5 mM KCl, 1% bovine serum albumin). For non-specific
binding, identical reactions were prepared with the addi-
tion of 0.1 μM unlabeled (cold) ligand. After 16-hours
incubation at 4°C, reactions were vacuum harvested
(Corning, Lowell, MA) onto 96-well GF/C filter plates that
were pre-soaked in 0.33% polyethyleneimine. The filters
were vacuum washed with 50 mM HEPES, pH 7.4, 500
mM NaCl, and 0.1% BSA. [125I]- bound insulin or IGF-I
was measured in a TopCount. Specific binding was calcu-
lated by subtracting non-specifically bound from the total
bound isotope [39].
Statistical Analysis
Data depicted in the graphs and tables represent the
means ± S.E.M.'s for 8-10 samples per group. Inter-group
comparisons were made using two-way ANOVA and post-
hoc Bonferroni's multiple comparison test of significance.
Statistical analyses were performed using the GraphPad
Prism 5 software (GraphPad Software, Inc., San Diego,
CA). Significant P-values are shown in the graphs or
included in the tables.
Results
Effects of NDEA and HFD on Serum Biomarkers of T2DM, 
Dyslipidemia, Body Weight, and Brain Weight
Fasting blood glucose and serum insulin concentrations
were significantly higher in NDEA-treated rats, with or
without HFD-feeding, relative to LFD fed, vehicle treated
controls, and the highest mean blood glucose and serum
insulin levels were detected in the HFD+NDEA group
(Figs 1A-B). Serum neutral lipid (Nile Red assay) (Fig.
1C), cholesterol (Fig. 1D), triglyceride (Fig. 1E), and free
fatty acid (Fig. 1F) levels were either unchanged or signif-
icantly reduced in the NDEA, HFD, and HFD+NDEA
treated groups relative to control, and the lowest mean
serum lipid levels were measured in the HFD ± NDEA
treated groups. Therefore, hyperglycemia and hyper-
insulinemia were features of chronic HFD feeding, and
these indices of peripheral insulin resistance were wors-
ened by prior exposure to low-dose NDEA. In addition,
early NDEA exposure alone was sufficient to cause mild
but significant peripheral insulin resistance. In contrast,
neither the NDEA exposure nor the chronic HFD feeding
caused hyperlipidemia, indicating that seemingly favora-
ble serum lipid profiles can exist in the context of periph-
eral insulin resistance or T2DM. These findings are similar
to those in a previous report in which the experimental
model was generated with much higher doses of NDEA
than used herein [62]. One possible interpretation of
these seemingly paradoxical results is that homeostasis
may have shifted toward increased storage of lipids/trig-
lycerides in adipose tissue, skeletal muscle, and/or liver.
Although initial mean body weights were similar among
the groups (data not shown), at the time of sacrifice, HFD
± NDEA treated rats were significantly heavier than LFD ±
NDEA treated rats (Fig. 1G). The mean brain weights didMolecular Neurodegeneration 2009, 4:54 http://www.molecularneurodegeneration.com/content/4/1/54
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Table 1: Primer Pairs Used for Quantitative Reverse Transcriptase Polymerase Chain Reaction Assays
Primer Direction Sequence (5'→3') Position (mRNA) Amplicon Size (bp)
Insulin For TTC TAC ACA CCC AAG TCC CGT C 145 135
Insulin Rev ATC CAC AAT GCC ACG CTT CTG C 279
Insulin Receptor For TGA CAA TGA GGA ATG TGG GGA C 875 129
Insulin Receptor Rev GGG CAA ACT TTC TGA CAA TGA CTG 1003
IGF-I For GAC CAA GGG GCT TTT ACT TCA AC 65 127
IGF-I Rev TTT GTA GGC TTC AGC GGA GCA C 191
IGF-I Receptor For GAA GTC TGC GGT GGT GAT AAA GG 2138 113
IGF-I Receptor Rev TCT GGG CAC AAA GAT GGA GTT G 2250
IGF-II For CCA AGA AGA AAG GAA GGG GAC C 763 95
IGF-II Rev GGC GGC TAT TGT TGT TCA CAG C 857
IGF-II Receptor For TTG CTA TTG ACC TTA GTC CCT TGG 1066 91
IGF-II Receptor Rev AGA GTG AGA CCT TTG TGT CCC CAC 1156
IRS-1 For GAT ACC GAT GGC TTC TCA GAC G 604 134
IRS-1 Rev TCG TTC TCA TAA TAC TCC AGG CG 737
IRS-2 For CAA CAT TGA CTT TGG TGA AGG GG 255 109
IRS-2 Rev TGA AGC AGG ACT ACT GGC TGA GAG 263
IRS-4 For ACC TGA AGA TAA GGG GTC GTC TGC 2409 132
IRS-4 Rev TGT GTG GGG TTT AGT GGT CTG G 2540
ChAT For TCA CAG ATG CGT TTC ACA ACT ACC 478 106
ChAT Rev TGG GAC ACA ACA GCA ACC TTG 583
AChE For TTC TCC CAC ACC TGT CCT CAT C 420 123
AChE Rev TTC ATA GAT ACC AAC ACG GTT CCC 542
APP For GCA GAA TGG AAA ATG GGA GTC AG 278 199
APP Rev AAT CAC GAT GTG GGT GTG CGT C 476
Tau For CGC CAG GAG TTT GAC ACA ATG 244 65
Tau Rev CCT TCT TGG TCT TGG AGC ATA GTG 308
SPTLC-1 For CTAACCTTGGGCAAATCGAA 2581 96
SPTLC-1 Rev TGAGCAGGGAGAAGGGACTA 2676Molecular Neurodegeneration 2009, 4:54 http://www.molecularneurodegeneration.com/content/4/1/54
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not differ significantly among the groups (Fig. 1H), but
the brain/body weight ratios were significantly reduced in
HFD ± NDEA relative to the LFD ± NDEA treated rats (Fig.
1I), in part due to their larger body masses.
NDEA and HFD-Induced Islet Hypertrophy and 
Steatohepatitis (Table 2 and Fig. 2)
Corresponding with the significantly increased blood glu-
cose and insulin levels, the HFD (Fig. 2B), NDEA (Fig.
2C), and HFD+NDEA (Fig. 2D) treated rats had conspicu-
ously hypertrophied pancreatic islets relative to
LFD+Vehicle (Veh) treated controls (Fig. 2A). Islet hyper-
trophy was not associated with inflammation, necrosis, or
histopathologic abnormalities in the exocrine pancreas.
Livers of LFD+Veh treated rats had regular chord-like
architectures with minimal steatosis and no inflammation
(Fig. 2E). NDEA, HFD, and HFD+NDEA treated rats all
had mixed patterns of macrovesicular and microvesicular
hepatic steatosis (Figs. 2F-2H) with scattered foci of lym-
phomononuclear cell inflammation (Fig. 2F and inset). In
addition, livers of NDEA ± HFD treated rats had conspic-
uous disorganization of the hepatic chord architecture
with scattered foci of hepatocellular necrosis (Figs. 2G-H).
A distinguishing feature of the NDEA+HFD exposed livers
was the strikingly greater prominence of hepatocellular
disorganization and steatosis relative to the other groups
(Fig. 2H). None of the livers showed evidence of malig-
nant transformation, i.e. tumors, nodules, or foci of ana-
plasia. The NDEA ± HFD abnormalities in liver
correspond with the effects of STZ treatment [63-65], and
are highly consistent with features of NASH in humans
[1,12,66]. Biochemical assays confirmed that chronic
HFD feeding ± NDEA treatment caused mild liver injury
and steatosis as demonstrated by the significantly
increased serum levels of ALT, and hepatic triglyceride
content (Table 2). The finding that the NDEA+HFD group
had the highest mean levels of serum ALT, and hepatic
Nile Red, cholesterol, and triglycerides suggests that the
effects of the NDEA plus HFD feeding were additive with
respect to liver injury.
SPTLC-2 For GGA CAG TGT GTG GCC TTT CT 1823 50
SPTLC-2 Rev TCA CTG AAG TGT GGC TCC TG 1872
CERS-1 For TGC GTG AAC TGG AAG ACT TG 947 98
CERS-1 Rev CTT CAC CAG GCC ATT CCT TA 1044
CERS-2 For CTC TGC TTC TCC TGG TTT GC 698 82
CERS-2 Rev CCA GCA GGT AGT CGG AAG AG 779
CERS-4 For CGA GGC AGT TTC TGA AGG TC 1240 72
CERS-4 Rev CCA TTG GTA ATG GCT GCT CT 1311
CERS-5 For GAC AGT CCC ATC CTC TGC AT 1254 92
CERS-5 Rev GAG GTT GTT CGT GTG TGT GG 1345
UGCG For GAT GCT TGC TGT TCA CTC CA 2682 67
UGCG Rev GCT GAG ATG GAA GCC ATA GG 2748
SMPD-1 For CAG TTC TTT GGC CAC ACT CA 1443 65
SMPD-1 Rev CGG CTC AGA GTT TCC TCA TC 1507
SMPD-3 For TCT GCT GCC AAT GTT GTC TC 2704 98
SMPD-3 Rev CCG AGC AAG GAG TCT AGG TG 2801
*Abbreviations: IGF = insulin-like growth factor; IRS = insulin receptor substrate; ChAT = choline acetyltransferase; AChE = acetylcholinesterase; 
APP = amyloid precursor protein; SPTLC = serine palmitoyltransferase; CERS = ceramide synthase; UGCG = UDP-glucose ceramide 
glucosyltransferase; SMPD = sphingomyelin phosphodiesterase; bp = base pair.
Table 1: Primer Pairs Used for Quantitative Reverse Transcriptase Polymerase Chain Reaction Assays (Continued)Molecular Neurodegeneration 2009, 4:54 http://www.molecularneurodegeneration.com/content/4/1/54
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Morris Water Maze Performance (Figure 3)
On Day 1 of testing (acquisition phase), NDEA treatment,
with or without chronic HFD feeding, significantly
impaired performance. On Day 2, HFD ± NDEA treated
rats performed significantly worse than LFD+Veh treated
controls. On Day 3, the NDEA+HFD group still performed
significantly worse than control, and although the
NDEA+LFD group had a longer mean latency for locating
the hidden platform, the difference from control was not
statistically significant. On Day 4, the mean latencies in
the NDEA-treated groups remained slightly higher than
Veh-treated LFD and HFD fed rats, but the inter-group dif-
ferences did not reach statistical significance. In essence,
although the mean (area under curve) latencies for locat-
ing and landing on the platform declined over time in all
groups, NDEA treatment alone impaired performance
during the acquisition phase, while combined
NDEA+HFD exposures significantly impaired both learn-
ing and memory.
Neuropathology of NDEA Exposure
LFD+Veh treated control Ammon's horn (CA1-CA4
regions) of the hippocampus (Fig. 4A) and the temporal
cortex (Fig. 4E) were richly populated by neurons with
excellent preservation of the architecture (Fig. 4A).
Chronic HFD feeding, NDEA-treatment, and NDEA+HFD
NDEA and HFD Feeding Cause T2DM Without Hyper-lipidemia: Long Evans rats were treated with 3 i.p. injections of vehicle  or NDEA (N = 12/group) on alternate days beginning on postnatal day 3 (P3) Figure 1
NDEA and HFD Feeding Cause T2DM Without Hyper-lipidemia: Long Evans rats were treated with 3 i.p. 
injections of vehicle or NDEA (N = 12/group) on alternate days beginning on postnatal day 3 (P3). From P21 
(weaning), rats were fed with high fat (60% of calories) or low fat (5% of calories) diets for 6 weeks. Serum harvested at the 
time of sacrifice and after an over-night fast was used to measure (A) glucose, (B) insulin, (C) Nile Red fluorescence (neutral 
lipids), (D) cholesterol, (E) triglycerides, and (F) free fatty acids. In addition, the mean (G) body weights, (H) brain weights, and 
(I) calculated brain weight/body weight ratios at the time of sacrifice are shown. Graphs depict the mean ± S.E.M. results for 
each group. Data were analyzed using repeated measures ANOVA and the post-hoc Dunn's test. Significant inter-group differ-
ences are indicated by the P-values over the bars.Molecular Neurodegeneration 2009, 4:54 http://www.molecularneurodegeneration.com/content/4/1/54
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NDEA Exposure and Chronic HFD Feeding Induce Pancreatic Islet hypertrophy and Steatohepatitis Figure 2
NDEA Exposure and Chronic HFD Feeding Induce Pancreatic Islet hypertrophy and Steatohepatitis. Long Evans 
rats were treated with sub-mutagenic doses of NDEA or vehicle (Veh) and then fed with high (HFD) or low fat (LFD) contain-
ing chow for 6 weeks (see legend to Figure 1). Pancreas and liver tissues were immersion fixed and embedded in paraffin. His-
tological sections were stained with H&E. Photomicrographs depict (A-D) pancreas or (E-H) liver from (A, E) LFD+Veh 
control, (B, F) HFD+Veh, (C, G) LFD+NDEA, and (D, H) HFD+NDEA treated rats. Note enlarged islets in Panels B, C, and D 
relative to A (arrows). (F) Chronic HFD feeding increased hepatic macrosteatosis (mainly large clear vacuoles; inset) and foci of 
lymph-mononuclear cell inflammation (encircled) relative to (E) control. Treatment with (G) NDEA resulted in disruption of 
the regular chord-like arrangement of hepatocytes, increased macro- (large) and microvesicular (small) steatosis, and increased 
foci of inflammation, and necrosis (inset). (H) NDEA+HFD exposure further disrupted the hepatic chord architecture, and 
increased the density of lipid vacuoles (inset), and foci of inflammation and necrosis. A-D, Original magnification 400×; E-H 
Original magnifications, Panels-80×; insets-650×.Molecular Neurodegeneration 2009, 4:54 http://www.molecularneurodegeneration.com/content/4/1/54
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exposure resulted in thinning of CA1 (Figs. 4B-4D), and
atrophy of the temporal cortex with loss of neurons man-
ifested by increased inter-neuronal spacing and on-going
apoptosis (Figs. 4F-H). In addition, glial cells were con-
spicuously increased in density in the temporal cortex of
NDEA+HFD treated rats (Fig. 4H).
Limited NDEA-Exposure and Chronic HFD Feeding Cause 
Sustained Abnormalities in Expression of AD-Associated 
Genes
To assess long-term effects of NDEA ± HFD on genes and
proteins that are aberrantly expressed in AD, we measured
amyloid-β-precursor protein (AβPP), Tau, choline acetyl-
transferase (ChAT), acetylcholinesterase (AChE), inter-
leukin 1β (IL-1β), IL-6, and tumor necrosis factor-alpha
(TNF-α) mRNA levels by qRT-PCR analysis (Table 3), and
Tau, phospho-Tau, AβPP, AβPP-Aβ, ChAT, AChE, glyceral-
dehyde-3-phosphate dehydrogenase (GAPDH), β-Actin,
GFAP, HNE, glycogen synthase kinase 3β (GSK-3β), and
pGSK-3β immunoreactivity by ELISA (Figs. 5 and 6). The
qRT-PCR studies demonstrated that chronic HFD feeding
alone reduced AβPP gene expression (P < 0.05), while
NDEA ± HFD significantly reduced Tau (P < 0001), ChAT
(P < 0.001), and IL-1β (P < 0.05) mRNA expression rela-
tive to LFD+Veh treated controls (Table 3). Although
AβPP mRNA expression was also reduced in the
NDEA+HFD group, the difference from control did not
reach statistical significance. The mean mRNA levels of
AChE, IL-6 and TNF-α were not significantly altered in the
HFD, NDEA, or NDEA+HFD groups relative to control.
ELISA results demonstrated that NDEA treatment alone
significantly increased AβPP-Aβ (P < 0.001) and HNE (P
< 0.001), and reduced ChAT (P < 0.01) and GFAP (P <
0.05) immunoreactivity relative to control (Figs. 5 and 6).
Chronic HFD feeding significantly increased pTau (P <
0.05) and Aβ PP (P < 0.05), and reduced the mean levels
of Chat (P < 0.05) relative to control (Figs. 5 and 6). The
combined NDEA+HFD exposures significantly increased
the mean ratio of pTau/Tau, indicating relatively higher
tau phosphorylation, and reduced the mean levels of Tau
(P < 0.001), AβPP-Aβ (P < 0.001), GSK-3β (P < 0.001),
ChAT (P < 0.001), GAPDH (P < 0.001), GFAP (P < 0.001),
β-actin (P < 0.05), and HNE (P < 0.001) relative to control
(Figs. 5 and 6). AChE immunoreactivity was not signifi-
cantly altered by NDEA and/or HFD feeding. Although
GSK-3β immunoreactivity was reduced by NDEA+HFD
exposure, the relative preservation of the pGSK-3β/GSK-
3β ratio indicates that constitutive GSK-3β activity in
brain was not significantly altered by these treatments.
Therefore, the increased pTau/Tau ratio measured in the
same samples may have been mediated by kinases other
than GSK-3β. The additive effects of HFD plus NDEA
exposure were demonstrated by the fact that the greater
reductions in ChAT, tau, β-actin, GFAP, and GAPDH, and
increases in the mean levels of pTau or pTau/Tau ratio
compared with the effects of either treatment/exposure
alone.
Limited NDEA-Exposure and Chronic HFD Feeding Cause 
Sustained Impairments in Insulin/IGF Signaling 
Mechanisms in the Brain
QRT-PCR analysis demonstrated significantly increased
levels of insulin (P < 0.05), IGF-1 (P < 001) and IRS-4 (P
< 0.001) in rats exposed to NDEA only, increased insulin
(P < 0.01) and IGF-2 receptor (P < 0.05), and decreased
IGF-1, IGF-1 receptor (P < 0.05), and IRS-1 in rats chron-
ically fed with the HFD, and reduced IGF-1 (P < 0.05),
insulin receptor (P < 0.05), IGF-1 receptor (P < 0.05), and
IRS-1 (P < 0.001) in rats treated with NDEA+HFD relative
to LFD fed controls (Table 4). Moreover, insulin, IGF-1,
insulin receptor, IGF-2 receptor, IRS-1, IRS-2, and IRS-4
mRNA levels were lowest in the NDEA+HFD treated
group. These impairments in the expression of genes
needed for proper insulin and IGF signaling are reminis-
cent of those detected in human brains with AD
[34,51,67].
NDEA and Chronic HFD Feeding Cause Hepatic and Brain 
Insulin and/or IGF-1 Resistance
NDEA exposure significantly reduced IGF-1 receptor
binding in liver (P < 0.001). Chronic HFD feeding signif-
icantly reduced IGF-1 receptor binding in liver (P < 0.05),
and both IGF-1 (P < 0.01) and insulin (P < 0.01) receptor
binding in brain. Combined NDEA+HFD exposures sig-
nificantly reduced both insulin receptor binding in liver
Table 2: Assays of Liver Injury or Hepatic Steatosis
Assay§ LFD+VEH LFD+NDEA HFD+VEH HFD+NDEA F-Ratio P-Value
Serum ALT (U/L) 17.3 ± 0.9 23.8 ± 3.9 30.6 ± 1.8** 33.5 ± 2.1** 10.08 < 0.0001
Nile Red (RFU/μg) 111.0 ± 2.6 128.3 ± 15.0 122.7 ± 6.1 147.9 ± 6.1* 2.77 0.06
Cholesterol (ng/mg) 360.5 ± 20.2 340.1 ± 33.9 435.4 ± 21.9 458.4 ± 19.7* 5.02 0.011
Triglycerides (μg/mg) 11.2 ± 1.5 10.8 ± 2.0 17.1 ± 0.8* 21.0 ± 1.4** 10.3 0.0003
§ALT = alanine transaminase, Nile Red, cholesterol, and tryglyceride levels were measured in liver tissue. RFU/μg = relative fluorescence units; Nile 
red, cholesterol and triglyceride measurements are relative to liver. Inter-group comparisons were made using ANOVA tests. For all 
measurements, df = 3/36. Significant differences relative to the LFD control group were demonstrated using the Dunnett's post-hoc multiple 
comparison test (*P < 0.05; **P < 0.01; ***P < 0.001).Molecular Neurodegeneration 2009, 4:54 http://www.molecularneurodegeneration.com/content/4/1/54
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(P < 0.5) and brain (P < 0.001), and IGF-1 receptor bind-
ing in liver (P < 0.001) and brain (P < 0.001) (Fig. 7). In
essence, insulin receptor binding was mainly associated
with chronic HFD feeding, with or without antecedent
NDEA exposure. However, the inhibitory effects of HFD
feeding and NDEA exposure appeared to be additive with
respect to insulin receptor binding in liver, and IGF-1
receptor binding in brain. These results suggest that the
NDEA exposure and chronic HFD-feeding differentially
mediate insulin and/or IGF resistance in liver and brain,
indicating that a given exposure can adversely affect organ
function in different ways and to dissimilar degrees.
NDEA-Mediated Increases in Pro-Ceramide Gene 
Expression
We investigated the potential role of pro-ceramide genes
as mediators of NDEA ± HFD associated neurodegenera-
tion because ceramides: 1) can be generated in brain and
liver [68-71]; 2) cause cytotoxicity and insulin resistance
[71,72]; and 3) are increased in brains with neurodegen-
eration [68,73-75]. Moreover, recent studies showed that
increased ceramide gene expression in liver correlates with
neurodegeneration in the context of obesity with T2DM
and NASH [38], and that in vitro ceramide exposure
causes neurodegeneration [72]. To assess the potential
role of ceramides and their sources in relation to neurode-
generation and insulin/IGF-1 resistance, we measured
mRNA levels of ceramide synthases (CER), UDP glucose
ceramide glycosyltransferase (UGCG), serine palmitoyl-
transferase (SPTLC), and sphingomyelin phosphodieste-
rases (SMPD) in liver and temporal lobe, due to their
demonstrated relevance to neurodegeneration [38,72].
The qRT-PCR analyses revealed significantly higher mean
levels of all 5 genes in livers of NDEA ± HFD-treated rela-
tive to LFD+Veh or HFD+Veh treated rats (Fig. 8). How-
ever, there was no additional burden produced by chronic
HFD, indicating that the NDEA exposure was sufficient to
significantly alter pro-ceramide gene expression in the
direction of increased ceramide production through both
biosynthesis and degradation pathways. With regard to
the temporal lobe, the effects of HFD and NDEA treat-
ment were more varied compared with liver. NDEA treat-
ment, with or without HFD feeding, increased expression
of CER4, UGCG and SMPD3, but decreased CER2, CER5,
and SPTLC1 mRNA levels (Table 5). In addition, HFD
feeding alone significantly increased SMPD1 and
decreased SPTLC1 expression relative to control. There-
fore, both NDEA and HFD feeding contributed to
increased ceramide generation in the brain, although
some enzymes involved in ceramide biosynthesis were
down-regulated, possibly as a protective/compensatory
mechanism to modulate its accumulation.
Discussion
We examined the degree to which limited early life NDEA
exposure exacerbates the effects of later chronic HFD feed-
ing on subsequent development of T2DM, NASH, and
neurodegeneration. The relevance of this work to human
disease is that, morbidity and mortality from major insu-
lin-resistance diseases have escalated over the past several
decades. Such trends more likely correspond with expo-
sure rather than genetic etiologies. Our principal hypoth-
esis is that shifts in lifestyles have led modern societies to
chronically consume excess fats, and also to increase our
exposures to pathogenic agents that cause insulin resist-
ance. We focused our investigations on nitrosamines, par-
ticularly NDEA, because in previous studies, STZ, a
nitrosamine-related chemical, was demonstrated to be
mutagenic in high doses [17], and to cause insulin-resist-
ance diseases at lower levels or after limited durations of
exposure [18-25,76]. However, since STZ is not generally
available in the environment or foodstuffs, whereas nitro-
samines and related compounds are widely present in our
environment and contaminate our foods, we hypothesize
that limited or chronic low-level exposures to nitro-
NDEA Treatment and Chronic HFD Feeding Impair Spatial  Learning and Memory: Long Evans rats were treated with  NDEA or vehicle (VEH) by i.p. injection (N = 12/group), and  then chronically fed with high fat (HFD) or low fat (LFD)  containing chow for 6 weeks (see Figure Legend 1) Figure 3
NDEA Treatment and Chronic HFD Feeding Impair 
Spatial Learning and Memory: Long Evans rats were 
treated with NDEA or vehicle (VEH) by i.p. injection 
(N = 12/group), and then chronically fed with high fat 
(HFD) or low fat (LFD) containing chow for 6 weeks 
(see Figure Legend 1). Rats were subjected to Morris 
Water Maze testing on 4 consecutive days. On Day 1, the 
platform was visible, but on Days 2-4, the platform was sub-
merged, and on Days 3-4, the water entry quadrant was ran-
domized. On each testing day, rats were given 3 trials, with a 
maximum of 120 seconds allowed to land on the platform, 
beyond which they were guided. Area under curve (AUC) 
was calculated for each series of trials each day. Graphs 
depict the mean ± S.E.M. AUC latencies for each group on 
each day of testing. Data were analyzed using the Kruskal-
Wallis one-way ANOVA and Dunn's multiple comparison 
post-hoc test for significance. Significant P-values relative to 
control (VEH+LFD) are indicated by asterisks (*P < 0.05; **P 
< 0.01).Molecular Neurodegeneration 2009, 4:54 http://www.molecularneurodegeneration.com/content/4/1/54
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Hippocampus and Temporal Lobe Degeneration Following NDEA-Exposure and/or HFD Feeding: Long Evans rats treated with  NDEA or vehicle (Veh) by i.p. injection (N = 12/group), and then chronically fed with high fat (HFD) or low fat (LFD) contain- ing chow for 6 weeks (see Figure Legend 1) Figure 4
Hippocampus and Temporal Lobe Degeneration Following NDEA-Exposure and/or HFD Feeding: Long Evans 
rats treated with NDEA or vehicle (Veh) by i.p. injection (N = 12/group), and then chronically fed with high fat 
(HFD) or low fat (LFD) containing chow for 6 weeks (see Figure Legend 1). Brains were immersion fixed and 
embedded in paraffin. Histological sections were stained with Luxol fast blue, H&E. Blue staining corresponds to myelinated fib-
ers and tracts. Photomicrographs depict (A-D) low magnification images of temporal cortex (TC) and hippocampal formation 
and (E-H) high magnification images of the temporal cortex. Note the thinning/reduced cell density within the CA1 region (Seg-
ment 1 of Ammon's Horn; arrows) of the hippocampal formation and slight thinning of the TC in brains of (B) Veh+HFD, (C) 
NDEA+LFD, and (D) NDEA+HFD treated rats relative to control (A) Veh+LFD). Higher magnification images of TC show (E) 
abundant pyramidal neurons (N) with regular organization and scattered glia (gl) in LFD+Veh treated control brains, (F) neuro-
nal atrophy and apoptosis (N; arrows) and increased glia (gl) in Veh+HFD treated rats, and (G, H) conspicuous neuronal loss 
with small clusters of apoptotic cells (encircled) in NDEA ± HFD-treated rats. In addition, as observed in the HFD-fed rat 
brains, glial cells were conspicuously increased relative to neurons in the (H) HFD+NDEA treated temporal cortex. Original 
magnifications: A-D, 40×; E-H, 400×. (Scale bar A-D, 200 microns; E-H 25 microns).Molecular Neurodegeneration 2009, 4:54 http://www.molecularneurodegeneration.com/content/4/1/54
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samines account for the current insulin resistance disease
epidemic in the United States. Moreover, given the clear
role of high dietary fat intake as a mediator of obesity,
T2DM, NAFLD/NASH, and cognitive impairment, we pro-
pose that the combined effects of HFD and NDEA expo-
sure additively promote development of insulin resistance
diseases.
The knowledge that: 1) human nitrosamine exposures
occur through many sources including, processed and pre-
served foods, tobacco smoke (direct or second hand), and
nitrate-containing fertilizers; and 2) nitrosamines are
mutagenic and cause tissue injury in manners similar to
STZ [17,19,27,29], prompted us to consider whether nit-
rosamines could have pathogenic roles in our insulin
resistance diseases epidemic. Although epidemiologic
studies have correlated obesity and high dietary fat intake
with rising rates of T2DM, NASH, and cognitive impair-
ment [1-3,5,6,77], experimental data are somewhat varied
depending on the model, and no studies have demon-
strated that obesity/T2DM is sufficient to cause significant
AD-type neurodegeneration with cognitive impairment.
In fact, the evidence convincingly informs us that these
factors alone are not sufficient, and instead serve as co-fac-
tors in the pathogenesis of neurodegeneration, including
AD. Therefore, we propose that high dietary fat intake
exacerbates the adverse effects of limited NDEA or other
nitrosamine exposures to cause insulin resistance dis-
eases.
We generated an experimental in vivo model in which rat
pups were treated with NDEA at doses that were 5- to 500-
fold lower than the cumulative doses used to cause cancer
[78-81], and beginning in early adolescence, we pair-fed
the rats with high (60%) or low (10%) fat content diets.
The use of young rats in these studies was inspired in part
by longitudinal studies of nuns demonstrating that neuro-
cognitive abnormalities occur decades earlier than the
onset of dementia, indicating that very early life exposures
may predispose individuals to develop AD, as well as
other neurodegenerative diseases [52,53], perhaps
through epigenetic events such as DNA methylation or
gene imprinting. Correspondingly, there is evidence that
DNA methylation and other epigenetic changes in DNA
increase with aging [82], and likely contribute to the
pathogenesis of diseases such as diabetes and neurode-
generation [82,83]. Moreover, there is experimental evi-
dence that nitrosamines, as well as other adduct forming
toxins that contaminate foods, can mediate DNA methyl-
ation [84,85]. Since it could take years for epigenetic mod-
ifications to cause disease, and the findings in the "Nun
Study" suggest that early events in life predispose individ-
uals to develop AD [53], we utilized an experimental ani-
mal model in which low-dose NDEA exposures were
administered early in life. The subsequent chronic HFD
feeding during adolescence, also fits with the human dis-
ease model. Therefore, our experimental approach ena-
bled us to examine effects of early life NDEA exposure on
later cognitive function and neurodegeneration in the
context of excess caloric intake, which is one of the major
modifying factors correlated with insulin resistance dis-
eases in our society.
Although the HFD feeding and NDEA treatments signifi-
cantly increased body weight relative to control, and
caused T2DM, characterized by fasting hyperglycemia,
hyperinsulinemia, and pancreatic islet hypertrophy
[86,87], the rats were not obese and they did not have
hyperlipidemia. On the other hand, the NDEA ± HFD
groups had steatohepatitis with hepatic insulin and/or
IGF-1 resistance which were more pronounced in rats that
had the combined versus individual NDEA or HFD expo-
sures. This suggests that HFD and NDEA function addi-
tively to promote NASH and T2DM. In contrast to the
C57BL/6 mouse model of HFD feeding in which NASH
was associated with obesity, T2DM, and hyperlipidemia
[38,39], the serological profile in the present model pro-
vided minimal evidence of hepatic insulin/IGF resistance.
Since the serum ALT levels were increased in the HFD
groups, perhaps biomarkers of hepatic injury in individu-
als with T2DM should be regarded as a potential indicator
of steatohepatitis.
The NDEA treatments and HFD feedings independently
caused significant deficits in spatial learning, and the
combined exposures had the added effect of impairing
learning and memory, again suggesting that the adverse
effects were additive. Therefore, curbing either or both
exposures could help prevent subsequent development of
cognitive impairment. A second point is that, although
the NDEA was delivered within a brief window early in
life, its impact on cognitive function was sustained in the
adults, similar to the effects of ic-STZ treatment [22,25].
The mechanism underlying these prolonged and possibly
progressive deficits may reside in the fact that nitro-
samines promote the formation of adducts that can serve
as persistent sources of oxidative stress, DNA damage, and
protein mal-folding or dysfunction [8,9,26,88], and ulti-
mately lead to epigenetic changes in gene expression.
Reduced levels of ChAT expression were observed in
brains of HFD, NDEA, and NDEA+HFD treated rats. In
addition, NDEA exposure without HFD feeding reduced
GFAP, but increased HNE and Aβ PP-Aβ, while
NDEA+HFD reduced GFAP, GAPDH, Tau, pGSK-3β,
AβPP-Aβ, and HNE immunoreactivities, and Tau and IL-
1β mRNA, but increased pTau and the pTau/Tau ratio.
Since HFD feeding alone had minimal effects on these
biomarkers of neurodegeneration, the differences in reac-
tion to NDEA versus NDEA+HFD could be attributed toMolecular Neurodegeneration 2009, 4:54 http://www.molecularneurodegeneration.com/content/4/1/54
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Effect of NDEA Exposure and Chronic HFD Feeding on Molecular Indices of Neurodegeneration Figure 5
Effect of NDEA Exposure and Chronic HFD Feeding on Molecular Indices of Neurodegeneration. Long Evans 
rats were treated with NDEA or vehicle (VEH) by i.p. injection (N = 12/group), and then chronically fed with high fat (HFD) or 
low fat (LFD) containing chow for 6 weeks (see Figure Legend 1). Temporal lobe protein homogenates were used to measure 
(A) Tau; (B) phospho (p)-Tau; (D) AβPP, (E) AβPP-Aβ, (F) GSK-3β, or (G) phospho (p)-GSK-3β by direct binding ELISA. In 
addition, the ratios of (C) pTau/Tau and (H) pGSK-3β/GSK-3β were calculated. Immunoreactivity was detected with HRP-con-
jugated secondary antibody and Amplex Red soluble fluorophor. Fluorescence light units (FLU) were measured (Ex 579 nm/Em 
595 nm) in a Spectromax M5, and results were normalized to protein content in the wells. Box plots depict mean ± S.E.M of 
results. Inter-group comparisons were made using ANOVA with the post-hoc Bonferroni test of significance. Significant P-val-
ues are indicated within the panels.Molecular Neurodegeneration 2009, 4:54 http://www.molecularneurodegeneration.com/content/4/1/54
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Effect of NDEA Exposure and Chronic HFD feeding on Molecular Indices of Oxidative Stress and Neurodegeneration Figure 6
Effect of NDEA Exposure and Chronic HFD feeding on Molecular Indices of Oxidative Stress and Neurodegen-
eration. Long Evans rats were treated with NDEA or vehicle (VEH) by i.p. injection (N = 12/group), and then chronically fed 
with high fat (HFD) or low fat (LFD) chow for 6 weeks (see Figure Legend 1). Temporal lobe protein homogenates were used 
to measure (A) choline acetyltransferase (ChAT), (B) acetylcholinesterase (AChE), (C) GFAP, (D) GAPDH, (E) β-Actin, or (F) 
4-hydroxynonenal (HNE) by direct binding ELISA. Immunoreactivity was detected with HRP-conjugated secondary antibody 
and Amplex Red soluble fluorophor. Fluorescence light units (FLU) were measured (Ex 579 nm/Em 595 nm) in a Spectromax 
M5, and results were normalized to sample protein content in the wells. Box plots depict mean ± S.E.M of results. Inter-group 
comparisons were made using ANOVA with the post-hoc Bonferroni test of significance. Significant P-values are indicated 
within the panels.Molecular Neurodegeneration 2009, 4:54 http://www.molecularneurodegeneration.com/content/4/1/54
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interactive or amplifying effects of chronic HFD feeding/
T2DM on early life, low-level NDEA exposure. This phe-
nomenon was particularly noticeable with respect to the
reductions in ChAT, which were modest in brains of rats
exposed to NDEA or the HFD, but striking in brains
exposed to NDEA plus HFD.
The NDEA-associated reductions in GFAP, Tau, and ChAT
expression in brain are of interest because similar observa-
tions were made in humans with AD, and in the ic-STZ
experimental animal model of AD-type neurodegenera-
tion [22,25,51]. The reduced levels of GFAP suggest that
glia (astrocytes) are targets of neurodegeneration. The
reductions in Tau and ChAT expression are noteworthy
because both genes are regulated by insulin/IGF stimula-
tion, their expression levels are reduced in AD [51], and
insulin/IGF resistance was demonstrated to be a promi-
nent adverse effect of limited and low-level NDEA expo-
sure resulting in neurodegeneration with cognitive
dysfunction, as also occurs in AD [51]. Similarly, the rela-
tive increases in pTau, and reductions in pGSK-3β (inac-
tive), GAPDH, and β-actin in the NDEA+HFD group
reflect adverse effects of impaired insulin/IGF signaling
with cytoskeletal collapse, increased oxidative stress, and
reduced energy metabolism, similar to the effects of both
i.c. STZ treatment in rats and sporadic AD in humans [51].
The effects of HFD, NDEA, or both exposures on AβPP
and AβPP-Aβ were varied, but the most striking findings
were significantly increased levels of AβPP-Aβ in NDEA-
treated rats, and paradoxically decreased levels of AβPP-
Aβ in brains of NDEA+HFD treated rats. Similarly, HNE
immunoreactivity was also increased in brain by limited
peripheral NDEA exposure, but these adverse effects of
NDEA were abolished by chronic HFD feeding. The find-
ings with respect to NDEA on AβPP-Aβ and HNE are con-
sistent with previous observations that oxidative stress
promotes AβPP-Aβ accumulation and lipid peroxidation
in the CNS [89]. On the other hand, it appears that HFD
feeding may have been somewhat protective, perhaps due
to alterations in membrane lipid composition leading to
enhanced intracellular signaling [90]. The fact that ChAT
expression and cognitive function were most impaired in
the NDEA+HFD group relative to control vis-à-vis low lev-
els of AβPP-Aβ highlights the controversial role of AβPP-
Aβ accumulation in relation to cognitive impairment in
AD.
Table 3: Effects of High Fat Diet and NDEA Exposure on Biomarkers of AD and Neuro-inflammation in Temporal Lobe
LFD LFD+NDEA HFD HFD+NDEA F-Ratio P-Value
AβPP 4.392 ± 0.423 3.966 ± 0.458 3.026* ± 0.215 3.228 ± 0.299 3.099 0.039
Tau 3.380 ± 0.272 2.689 ± 0.255 3.310 ± 0.270 1.938*** ± 0.209 7.023 0.001
ChAT 0.170 ± 0.016 0.147 ± 0.026 0.164 ± 0.014 0.115§ ± 0.007 0.001
AChE 0.824 ± 0.081 1.080 ± 0.137 0.747 ± 0.099 0.795 ± 0.048
IL-1β 0.047 ± 0.004 0.047 ± 0.010 0.052 ± 0.005 0.023* ± 0.003 4.627 0.008
IL6 0.052 ± 0.006 0.045 ± 0.006 0.050 ± 0.005 0.034 ± 0.005
TNF-α 0.022 ± 0.002 0.035 ± 0.005 0.034 ± 0.005 0.036 ± 0.004
Gene expression was measured by qRT-PCR with results normalized to 18S rRNA (see Methods). Values correspond to mRNA/18S × 10-6. Inter-
group comparisons were made using ANOVA tests. For all measurements, df = 3/36. Significant differences relative to the LFD control group were 
demonstrated using the Dunnett's post-hoc multiple comparison test (*P < 0.05; **P < 0.01; ***P < 0.001). For ChAT, the ANOVA test was not 
significant, but the mRNA levels were significantly different from control in the HFD+NDEA treated group by T-test analysis.
Table 4: Effects of High Fat Diet and NDEA Exposure on Biomarkers of Insulin and IGF Resistance in Temporal Lobe
LFD LFD+NDEA HFD HFD+NDEA F-Ratio P-Value
Insulin 0.093 ± 0.011 0.155* ± 0.015 0.181** ± 0.028 0.069 ± 0.008 9.1450 < 0.0001
IGF-1 0.170 ± 0.012 0.253** ± 0.029 0.101* ± 0.015 0.101* ± 0.007 16.4000 < 0.0001
IGF-2 2.336 ± 0.285 2.414 ± 0.675 1.718 ± 0.219 2.004 ± 0.179 19.3400 < 0.0001
Insulin R 1.060 ± 0.129 0.977 ± 0.070 0.997 ± 0.117 0.634* ± 0.073 3.6360 0.0210
IGF-1R 0.814 ± 0.111 1.027 ± 0.098 0.482* ± 0.047 0.485* ± 0.059 10.3700 < 0.0001
IGF-2R 0.649 ± 0.049 0.721 ± 0.107 0.893* ± 0.051 0.540 ± 0.053 4.5660 0.0080
IRS-1 0.393 ± 0.031 0.439 ± 0.040 0.244** ± 0.013 0.185*** ± 0.016 19.3400 < 0.0001
IRS-2 1.678 ± 0.211 2.652 ± 0.406 1.127 ± 0.104 1.300 ± 0.166
IRS-4 0.029 ± 0.005 0.153*** ± 0.030 0.049 ± 0.007 0.025 ± 0.004 15.0000 < 0.0001
Gene expression was measured by qRT-PCR with results normalized to 18S rRNA (see Methods). Values correspond to mRNA/18S × 10-6. Inter-
group comparisons were made using ANOVA tests. For all measurements, df = 3/36. Significant differences relative to the LFD control group were 
demonstrated using the Dunnett's post-hoc multiple comparison test (*P < 0.05; **P < 0.01; ***P < 0.001).Molecular Neurodegeneration 2009, 4:54 http://www.molecularneurodegeneration.com/content/4/1/54
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NDEA exposure and HFD feeding independently
impaired insulin and IGF-1 signaling mechanisms in liver
and brain, and in general, the combined exposures further
reduced both hepatic and brain insulin and IGF-1 recep-
tor binding compared with HFD feeding alone. Therefore,
brain and hepatic insulin/IGF-1 resistance can be effectu-
ated by either insult. Although impairments in binding to
the insulin and IGF-1 receptors in brain could be
explained in part by reduced expression of those receptors
or receptor-bearing cells in rats treated with NDEA+HFD,
generally, this was not the case for the NDEA-treated or
HFD-fed groups in which the receptor expression was
either elevated or similar to control. Most likely, the
impaired receptor binding with attendant reduced expres-
sion of IRS signaling molecules mediated the insulin/IGF
resistance. Moreover, the reductions in IGF-1 expression
could account for progressive loss of IGF-1 receptor bear-
ing cells in vivo. In some instances, ligand expression was
increased, suggesting that compensatory responses had
occurred due to insulin/IGF-1 resistance as occurs in
T2DM.
NDEA Exposure and Chronic HFD Feeding Impair Insulin and IGF-1 Receptor Binding in Liver and Brain Figure 7
NDEA Exposure and Chronic HFD Feeding Impair Insulin and IGF-1 Receptor Binding in Liver and Brain. Long 
Evans rats were treated with NDEA or vehicle (VEH) by i.p. injection (N = 12/group), and then chronically fed with high fat 
(HFD) or low fat (LFD) containing chow for 6 weeks (see Figure Legend 1). Competitive equilibrium binding studies were used 
to measure specific insulin and IGF-1 binding to their corresponding receptors. Reactions were incubated with 50 nCi/ml of 
[125I] (2000 Ci/mmol; 50 pM) insulin or IGF-I in binding buffer in the presence or absence of 0.1 μM unlabeled ligand. Radiola-
beled bound ligand was harvested onto 96-well GF/C filter plates and measured in a TopCount. Specific binding was calculated 
by subtracting non-specifically bound from the total bound isotope. Box plots depict mean ± S.D. of specific binding for (A, B) 
insulin and (C, D) IGF-I in (A, C) liver and (B, D) temporal lobe. Inter-group comparisons were made using ANOVA with the 
post-hoc Bonferroni test of significance. Significant P-values are indicated within the panels.Molecular Neurodegeneration 2009, 4:54 http://www.molecularneurodegeneration.com/content/4/1/54
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Effect of NDEA exposure and chronic HFD feeding on pro-ceramide gene expression in liver Figure 8
Effect of NDEA exposure and chronic HFD feeding on pro-ceramide gene expression in liver. Long Evans rats 
treated with NDEA or vehicle (VEH) by i.p. injection (N = 8/group), and then chronically fed with high fat (HFD) or low fat 
(LFD) containing chow for 6 weeks (see Figure Legend 1). Total RNA extracted from liver tissue was reverse transcribed using 
random oligodeoxynucleotide primers, and the resulting cDNA templates were used in qRT-PCR assays to measure (A) Cera-
mide synthase (CER) 2, (B) CER4, (C) Serine palmitoyltransferase 2 (SPTLC2), (D) UDP-glucose ceramide glycoysltransferase 
(UGCG), or (E) sphingomyelin phosphodiesterase 1 (SMPD1). The mRNA levels were normalized to 18S rRNA measured in 
the same templates. Graphs depict the mean ± S.E.M. levels of gene expression. Inter-group comparisons were made using 
ANOVA with the post-hoc Bonferroni test of significance. Significant P-values are indicated within the panels.Molecular Neurodegeneration 2009, 4:54 http://www.molecularneurodegeneration.com/content/4/1/54
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The mechanisms of sustained brain and liver insulin- and
IGF-1 resistance in the context of NDEA exposure ± HFD
feeding are not well understood. The fact that NDEA ±
HFD feeding caused NASH, led us to investigate whether
toxic lipids stemming from NASH-related injury could
contribute to NDEA-mediated neurodegeneration. Since
pro-ceramide genes are increased in experimental models
of NASH [68,71,74,91], and ceramides cause neurodegen-
eration, pro-inflammatory cytokine activation, and insu-
lin resistance [4,38,68,71-74,92,93], we measured mRNA
levels of pro-ceramide genes in liver and brain. Those
studies revealed strikingly increased levels of several genes
involved in ceramide generation via both biosynthesis
and degradation pathways in livers of NDEA-treated rats,
with virtually no additional impact of HFD feeding. Since
both NDEA and ceramides are lipid soluble [94,95], and
therefore likely to readily cross the blood-brain barrier,
NDEA exposure could cause CNS insulin resistance and
chronic injury by dual mechanisms: 1) direct neurotoxic
injury with locally increased production of adducts and
pro-ceramide gene expression; and 2) increased hepatic
ceramide synthesis leading to the establishment of a liver-
brain axis of neurodegeneration. Correspondingly, the
qRT-PCR results suggest that hepatic-origin ceramide is
generated by both synthetic and degradative pathways in
NDEA-treated rats, whereas in the brain, ceramide gene
expression was strikingly increased via degradative path-
way mechanisms, and inhibited via the synthetic path-
ways. Preliminary studies suggest that in vivo
intraperitoneal administration of toxic ceramides is suffi-
cient to cause brain insulin resistance, neurodegeneration,
and cognitive impairment (Tong, et al, unpublished).
Conclusions
We demonstrated that limited, low-level exposure to sub-
mutagenic doses of NDEA, together with chronic HFD
feeding, act additively in causing peripheral, hepatic and
brain insulin and IGF-1 resistance associated with T2DM,
NAFLD/NASH, and neurodegeneration. The neurodegen-
eration had features in common with AD, including
impairments in learning and memory, cholinergic func-
tion, and neuronal cytoskeletal gene and protein expres-
sion. These abnormalities were associated with increased
pro-ceramide gene expression, and since ceramides pro-
mote insulin resistance, neuro-inflammation, and neuro-
degeneration, characterization and measurement of
ceramides and related lipotoxins in blood may prove use-
ful as biomarkers of insulin-resistance disease progression
toward T2DM, NASH, or AD. The molecular and bio-
chemical abnormalities detected are quite reminiscent of
the findings in the ic-STZ model [51]. Altogether, these
results raise concerns about the double insult of chronic,
low-level nitrosamine exposure and high dietary fat con-
sumption as major mediators of our insulin resistance dis-
ease epidemic.
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